Fall neuroscience seminar series kicks off with talk on Parkinson’s Disease on September 25

The Lake Forest College Neuroscience Program, Nu Rho Psi (the national neuroscience honorary) and  SYNAPSE (the college’s neuroscience student organization) invites the public to a lecture entitled “CaV1.3-Selective L-Type Calcium Channel Antagonists: Novel Therapeutics to Slow the Progression of Parkinson’s Disease” by  Dr. Richard Silverman (Northwestern University) on Wednesday, September 25, at 4:15 pm, in Meyer Auditorium located in Hotchkiss Hall. A reception will begin at 4:00 pm.

Professor Silverman received his BS degree in chemistry from Pennsylvania State University and his PhD degree in organic chemistry from Harvard University, with time off for a two-year military obligation from 1969-1971. After two years as a NIH postdoctoral fellow in biochemistry at Brandeis University, he joined the chemistry faculty at Northwestern University. In 1986 he became Professor of Chemistry and Professor of Biochemistry, Molecular Biology, and Cell Biology. In 2001 he was named the Charles Deering McCormick Professor of Teaching Excellence, and since 2004 he has been the John Evans Professor of Chemistry.

His research can be summarized as investigations of the molecular mechanisms of action, rational design, and syntheses of potential medicinal agents.

His recent awards include Arthur C. Cope Senior Scholar Award of the American Chemical Society (ACS) (2003), Alumni Fellow Award from Pennsylvania State University (2008), Medicinal Chemistry Hall of Fame of the ACS (2009), the Perkin Medal (2009), the E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances from the ACS (2011), Fellow of the ACS (2011), Sato Memorial International Award of the Pharmaceutical Society of Japan (2012), Roland T. Lakey Award of Wayne State University (2013), BMS-Smissman Award of the ACS (2013), and the Centenary Prize (2013).   

Professor Silverman has published over 300 research articles, holds 48 domestic and foreign patents, and has written four books (The Organic Chemistry of Drug Design and Drug Action translated into German and Chinese).  He is the inventor of LyricaTM, a drug marketed by Pfizer since 2005 for epilepsy, neuropathic pain, and fibromyalgia; currently he has completed Phase I clinical trials of another drug for infantile spasms.

The event is open and free to the public. Parking is available on Middle Campus (enter at the College and Sheridan Road intersection).